Overview

A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus

Status:
NOT_YET_RECRUITING

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal. Ultrasound devices will be used to check the stomach content after a test meal. The study can last approximately 28 weeks.

Phase:

PHASE1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

dulaglutide